LSU AgCenter selects vendor for therapeutic cannabis program
As of September 14, 2017, the LSU AgCenter finalized their agreement with GB Sciences Louisiana, LLC, a wholly-owned subsidiary of GB Sciences, Inc., to produce therapeutic cannabis products for qualifying patients.
GB Sciences is a cannabis company focused on biopharmaceutical development, and has filed patent applications for use of cannabis with chronic pain and heart therapies, as well as chronic arthritis, Crohn’s disease, inflammatory bowel disease and asthma.
GB Sciences will produce therapeutic cannabis under the LSU AgCenter’s license for patients with very specific conditions.
In compliance with the Alison Neustrom Act, approved medical care providers will oversee patients with debilitating conditions including cancer, HIV, epilepsy and spasticity. Patients who have exhausted other medical options without a positive result may be recommended therapeutic cannabis by their practitioner, through specific delivery methods and specified dosages.
The LSU AgCenter has been working closely with state regulators including the Louisiana Department of Agriculture and Forestry, the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners to ensure that patient and public safety are at the forefront.
The Louisiana State Board of Medical Examiners has developed stringent guidelines for doctors to recommend therapeutic cannabis, including regular follow-ups and reporting.
Delivery methods are limited to oils, oral methods such as pills, sprays or chewables, topical applications, transdermal patches and suppositories. Louisiana law does not allow for any product to be inhaled, raw or smoked.
GB Sciences will begin renovation of their production facility immediately and anticipate product availability for patients by the middle of next year. The production facility will not be located on LSU’s campus, and no students as well as anyone under 21 years old will be employed in the facility.
Under the terms of the agreement, the LSU AgCenter will receive $3.4 million or 10 percent of gross revenue, whichever is greater, over five years. GB Sciences will support LSU AgCenter research through funding for personnel, laboratory research space and equipment and an additional monetary contribution for research initiatives.
As the licensee, the LSU AgCenter is authorized to conduct research on therapeutic cannabis. The LSU AgCenter has had preliminary discussions with Pennington Biomedical Research Center and the Health Science Centers in New Orleans and Shreveport on opportunities for research collaboration.
Research will likely include variety development, growth management practices, extraction techniques, compound identification and isolation, drug delivery methods and efficacy testing.
GB Sciences will be responsible for the cultivation, extraction, processing, and production of therapeutic cannabis and will provide and perform all other necessary activities to provide usable theriapeutic cannabis products for patients through licensed dispensary pharmacies.
As a public institution of higher education, the LSU AgCenter’s partnership with GB Sciences represents a first in the therapeutic cannabis industry.
Representatives from the LSU AgCenter visited the GB Sciences production facility in Las Vegas, Nevada.
The LSU AgCenter chose GB Sciences following a rigorous selection process for this collaboration.
No taxpayer dollars will be spent on the project.
The LSU AgCenter and GB Sciences anticipate production facility construction and renovations to be completed in the first quarter of 2018, and anticipate product availability by mid-year. All products must be sold in a dispensary approved by the Louisiana Board of Pharmacy.
- Positive status for Human Immunodeficiency Virus (HIV)
- Acquired Immune Deficiency Syndrome (AIDS)
- Cachexia or wasting syndrome
- Seizure disorders
- Crohn’s disease
- Muscular dystrophy
- Multiple sclerosis
Allowable Delivery Methods
- No raw or inhaled products
- Oils, extracts, tinctures or sprays
- Solid oral dosage forms, e.g., capsules or pills
- Liquid oral dosage forms, e.g., solutions or suspensions
- Edible dosage forms (chewable)
- Topical applications, oils or lotions
- Transdermal patches
Patients with qualifying medical conditions should discuss medical opportunities with their physicians.
The Louisiana State Board of Medical Examiners has developed rules relative to the recommendation of therapeutic cannabis by licensed physicians. Regulations include mandatory testing and qualifying by physicians and regular reporting of patient status. Additional information on the Board of Medical Examiners can be found at www.lsbme.la.gov .
The Louisiana State Board of Medical Examiners requires physicians complete an online registration course. CLICK HERE for the online Board Orientation and Courses.
For information on the Physician requirements and instructions for application, view attached .pdf.: LSBME PACKETpdf
Louisiana law limits the number of pharmacies to dispense therapeutic cannabis to ten licenses. These pharmacies will be selected by the Louisiana Board of Pharmacy through an application process. Additional information can be found at www.pharmacy.la.gov .
Regulations and Enforcement
The Louisiana Department of Agriculture and Forestry are named as the regulatory agency for the licensees. Information on the regulations can be found at www.ldaf.state.la.us, or click here for the current rules.